title: Response of authors to Ganju and Dias' comments on 'Inclusion of Placebos and Blinding for Ascending Dose First-in-Human Studies and Other Underpowered Phase 1 Studies Has Not Been Justified and on Balance is Not Useful' by D. A. Parasrampuria and L. Z. Benet.
authors.affiliation: Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, CA, USA.
authors.forename: Dolly A
authors.initials: DA
authors.lastname: Parasrampuria
authors.affiliation: Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, CA, USA. leslie.benet@ucsf.edu.
authors.forename: Leslie Z
authors.initials: LZ
authors.lastname: Benet
mesh_terms: D017321:Clinical Trials, Phase I as Topic / Q000379:methods*; D006801:Humans; D015990:Placebo Effect; D012107:Research Design